Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.

C GalloisE S BergenÉ AuclinS PernotJ HiguéI TrouilloudY TouchefeuA TurpinT MazardA Sartore-BianchiH PrenenA AlbertiL PillaS CuissyV WookeyA PerretC MelchiorP ArtruO DubreuilA DrouillardS DoatJ LavoléD BasileG PerkinsM JaryS StintzingJ JosD TougeronJ Taieb

Published in: ESMO open (2024)

This real-world study showed that in patients with BRAF V600E-mutated mCRC treated with encorafenib/cetuximab +/- binimetinib, efficacy and safety data confirm those reported in the BEACON registration trial. The main poor prognostic factors for this treatment are synchronous metastases and ECOG-PS >1.

Keyphrases

metastatic colorectal cancer
prognostic factors
wild type
clinical trial
electronic health record
big data
phase iii
squamous cell carcinoma
phase ii
randomized controlled trial
deep learning
machine learning
newly diagnosed